-
-
TRIKAFTA
- QTY 84
- 100-50-75
- TABLET SEQ
- Near 77381
ELEXACAFTOR; TEZACAFTOR; IVACAFTOR (el EX a KAF tor; TEZ a KAF tor; EYE va KAF tor) treats cystic fibrosis (CF). It works by helping your body balance the level of salt and water in your lungs. This prevents the buildup of mucus and reduces the symptoms of CF.
Change Location
Set Price Drop Alert for:
TRIKAFTA
- QTY 84
- 100-50-75
- TABLET SEQ
What does Supply mean?
If your selected quantity is intended to last longer than one month, please recheck the price using the 3-months supply option. In some cases, the estimated drug price may vary depending on the supply duration.
More Ways to Save On:
TRIKAFTA
- QTY 84
- 100-50-75
- TABLET SEQ
You may find alternative ways to save with this medication. Talk to your pharmacist about the potential option(s) noted below.
Change Form
Medicine Chest
TRIKAFTA Lifestyle Interactions
-
Elexacaftor 100mg, Tezacaftor 50mg, Ivacaftor 75mg, Oral tablet
• Interaction: Grapefruit juice• Severity: Major• Notes for Consumers: Do not take Grapefruit juice or grapefruit-containing foods and Elexacaftor; Tezacaftor; Ivacaftor together without talking to your health care professional. Side effects from Elexacaftor; Tezacaftor; Ivacaftor may get worse if you drink Grapefruit juice or consume grapefruit-containing foods. Notify your prescriber if you have any new or worsening side effects such as dark yellow or brown urine, general ill feeling or flu-like symptoms, light-colored stools, loss of appetite, nausea, right upper belly pain, unusually weak or tired, yellowing of the eyes and skin.• Notes for Professionals: Advise patients to avoid grapefruit juice or grapefruit-containing foods while taking elexacaftor; tezacaftor; ivacaftor as coadministration may increase elexacaftor; tezacaftor; ivacaftor exposure. Elexacaftor, tezacaftor, and ivacaftor are CYP3A4 substrates (ivacaftor is a sensitive substrate); fosamprenavir is a strong CYP3A4 inhibitor. Coadministration of a strong CYP3A4 inhibitor increased elexacaftor exposure by 2.8- fold, tezacaftor exposure by 4.5-fold, and ivacaftor exposure by 15.6-fold.
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.
